Bifidobacterium animalis subsp. lactis BB-12 for Gut Transit
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Bifidobacterium animalis subsp. lactis BB-12 in Gut Transit grades Tier B — preliminary evidence. Effective, but with safety or population caveats.
B 🟡 B Preliminary Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.64
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
65%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.644
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials
Finding: Probiotics reduced whole gut transit time by 12.4 h (95% CI -22.3 to -2.5) and increased stool frequency by 1.3 BM/wk (95% CI 0.7-1.9); the B. lactis subgroup was specifically significant (frequency WMD +1.5 BM/wk, 95% CI 0.7-2.3; consistency SMD +0.46, 95% CI 0.08-0.85) whereas L. casei Shirota was not.
View on PubMed Effects of Bifidobacterium animalis subspecies lactis supplementation on gastrointestinal symptoms: systematic review with meta-analysis
Finding: B. animalis subsp. lactis increased defecation frequency (SMD 0.26, 95% CI 0.13-0.39) and reduced colonic transit time in short-term (<=14 d) use (SMD -0.34, 95% CI -0.62 to -0.07), with improved stool consistency in people without GI symptoms (SMD 0.76, 95% CI 0.44-1.08); no effect on abdominal pain or bloating.
View on PubMed Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials
Finding: Probiotics improved treatment response (369/647 vs 252/567; RR 1.28, 95% CI 1.07-1.52, p=0.007) and stool frequency (SMD 0.71, 95% CI 0.37-1.04), an effect driven specifically by Bifidobacterium lactis but not probiotic mixtures, B. coagulans or L. casei Shirota; no effect on stool consistency (SMD 0.26, p=0.08) and synbiotics showed no benefit.
View on PubMed Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults
Finding: B. lactis HN019 reduced WGTT dose-dependently over 14 days (high dose 49+/-30 to 21+/-32 h, p<0.001; low dose 60+/-33 to 41+/-39 h, p=0.01) versus no change on placebo (43+/-31 to 44+/-33 h), and reduced 8/9 functional GI symptoms at high dose.
View on PubMed Matrix Effects on the Delivery Efficacy of Bifidobacterium animalis subsp. lactis BB-12 on Fecal Microbiota, Gut Transit Time, and Short-Chain Fatty Acids in Healthy Young Adults
Finding: BB-12 (~10^10 CFU/day) delivered in yogurt smoothie or capsule did NOT significantly alter gut transit time, gut microbiota composition, or fecal SCFA concentration; only relative abundance of B. animalis rose with the prefermented/postfermented smoothie (P<0.0001).
View on PubMed Randomized, double-blind, placebo-controlled study of synbiotic yogurt effect on the health of children
Finding: Synbiotic (n=76) vs placebo (n=73) gave fewer fever days (1.85 vs 1.95, p<0.05) and better social/school functioning, with MORE days of >=3 loose/watery stools in the synbiotic group (p<0.05), which authors attributed to an accelerating effect of BB-12 + inulin on intestinal transit.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
GRN 856 - Bifidobacterium animalis subsp. lactis strain BB-12; Status: FDA closure with no objections; No-Objection Letter Date: December 9, 2019; Intended Use: 'For use as an ingredient in conventional foods for use by the general population, excluding foods subject to regulation by the USDA, at levels intended to provide 5 x 10^11 CFU/serving.' Notifier: Chr. Hansen, Inc. (Milwaukee, WI). source↗
L4b EU EFSA
Cautious
Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), 'natural immune function' (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentratio… source↗
L4c UK NHS
Cautious
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema. Probiotics are generally classed as food rather than medicine, which means they don't go through t… source↗
L5a NIH Office of Dietary Supplements
Supportive
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others. The strain has been granted GRAS (generally recognized as safe) status in the United States, and the species has QPS (qualified presumption of safety) status … source↗
L5d Harvard Health
Supportive
Probiotics that contained Bifidobacterium appeared to be the most effective. ... probiotics increased 'gut transit time' by 12.4 hours, increased the number of weekly bowel movements by 1.3, and helped soften stools, making them easier to pass. ... there's still not enough evidence to recommend a specific probiotic for constipation source↗
L5e Specialty Society (condition-mapped)
Cautious
The routine use of probiotics is not recommended in the treatment of childhood constipation. source↗